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Summary Context: Community-acquired pneumonia (CAP) is common among adults
and contributes considerably to morbidity and mortality.
Objective: To compare the safety and efficacy of gemifloxacin to high-dose
amoxicillin/clavulanate for the treatment of CAP of suspected pneumococcal origin.
Design: Randomized, multicentre, double-blind, double-dummy, parallel group
Phase III study.
Setting and participants: From September 1998 to July 1999, 324 patients with
CAP were randomized at 102 centers in France, Poland and the Republic of South
Africa.
Intervention: Patients were double-blind randomized to receive either oral
gemifloxacin 320mg once daily for 7 days or oral amoxicillin/clavulanate 1 g/125mg
three times daily for 10 days.
Main outcome measures: The main outcome measures were clinical, bacteriolo-
gical, and radiological responses at the end of therapy (day 12–14) and follow-up
(day 24–30) visits.
Results: In 228 PP patients, clinical resolution at follow-up was 88.7% for 7-day
gemifloxacin and 87.6% for 10-day amoxicillin/clavulanate [95% CI, 7.3, 9.5]. In
249 PP patients, clinical resolution at end of therapy was 95.3% for 7-day
gemifloxacin vs. 90.1% for 10-day amoxicillin/clavulanate [95% CI, 1.2, 11.7].
Bacteriologic response rates for the PP patients at end of therapy were 96.3% for 7-
day gemifloxacin and 91.8% for the amoxicillin/clavulanate group [95% CI, 4.7,
13.6]. Bacteriologic response rates at follow-up were 87.2% for 7-day gemifloxacin
and 89.1% for the amoxicillin/clavulanate group [95% CI, 15.0, 11.2]. Specifically
gemifloxacin eradicated 95.7% of Streptococcus pneumoniae including penicillin and
macrolide resistant strains. Radiological response rates for the PP patients at end of
therapy were 89.1% for 7-day gemifloxacin and 87.6% for the amoxicillin/clavulanate
group. The most frequently reported drug-related events were in the gemifloxacin
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group, diarrhea (6.0%) and rash (3.0%) and in the amoxicillin/clavulanate group,
diarrhea (11.1%) and fungal infection, vaginitis and vomiting (each 2.0%). Overall
there were statistically fewer withdrawals due to lack of therapeutic effect in the
gemifloxacin group compared with the amoxicillin/clavulanate cohort, (95% CI,
8.8;0.6; P ¼ 0:03).
Conclusion: Gemifloxacin 320mg once daily for 7 days was found to be clinically,
bacteriologically, and radiologically as effective as 10 days of amoxicillin/
clavulanate 1 g/125mg three times daily for the treatment of suspected pneumo-
coccal CAP.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Community-acquired pneumonia (CAP) remains an
important disease and severe CAP has been shown
to be associated with considerable morbidity,
mainly as hospitalization and mortality, particularly
among the elderly and those with co-morbidities.1,2
For this reason, early diagnosis and early empiric
antimicrobial therapy are essential to the effective
management of CAP. A diagnosis of CAP is based on
signs and symptoms such as fever, increased cough,
dyspnoea, rapid respiratory rate and sputum
production, as well as clinical signs of consolidation
demonstrated by radiological evidence.
The most common bacterial causes of CAP are
Streptococcus pneumoniae, and atypical patho-
gens, such as Mycoplasma pneumoniae, Chlamydia
pneumoniae and Legionella species, in addition to a
mixed etiology in up to 30% of infections.3–6 The
changing susceptibility patterns of these patho-
gens, in particular that of S. pneumoniae, have
raised concerns about the efficacy of currently
available therapies and have prompted the devel-
opment and evaluation of new agents. Penicillin-
resistant strains of S. pneumoniae have been
identified world-wide,7 and resistance to other
antibacterials such as cephalosporins and macro-
lides is high among isolates of S. pneumoniae
expressing high-level penicillin resistance.8,9 Ac-
cordingly, the specific recognition and treatment of
CAP caused by S. pneumoniae has become increas-
ingly important.
Many currently available antimicrobials must be
given more than once a day, which can lead to
compliance issues.10 The need for a convenient,
shorter course, once-daily agent with broad-spec-
trum activity is thus apparent.
Gemifloxacin is a new quinolone antibacterial
agent with such a broad spectrum of antibacterial
activity. It has excellent activity against both
Gram-positive and Gram-negative organisms, in-
cluding potent antibacterial activity against Strep-
tococcus species (spp) and methicillin-susceptible
Staphylococcus spp. In vitro studies using clinical
isolates have shown gemifloxacin to be highly
active against penicillin- and macrolide-resistant
strains of S. pneumoniae. In contrast to other
reference quinolones gemifloxacin, due to its dual
mode of action, retained good activity against
clinical isolates of S. pneumoniae that were
resistant to other members of the quinolone
class.11 Gemifloxacin acts by the simultaneous
inhibition of both bacterial DNA gyrase and DNA
Topoisomerase IV at therapeutically achievable
tissue concentrations, thereby interfering with
bacterial DNA replication.11 Gemifloxacin has also
demonstrated excellent activity against b-lacta-
mase-producing and macrolide-resistant isolates of
Haemophilus influenzae in addition to all the
respiratory atypical pathogens.
Based on the in vitro activity of gemifloxacin
against respiratory pathogens and its pharmacoki-
netic profile,11 a dose of 320mg once daily provides
serum levels for adequate bactericidal activity for
patients with CAP. Hence, the purpose of the
current study was to assess the clinical, bacter-
iological, and radiological efficacy of gemifloxacin
320mg once daily for seven days with that of
amoxicillin/clavulanate 1 g/125mg three times
daily for 10 days in the treatment of CAP of
suspected pneumococcal origin. The rationale for
comparing gemifloxacin to 1 g amoxicillin in a fixed
combination was that the study was conducted
primarily in France where there is a high rate of
penicillin-resistant S. pneumoniae. This dosing of b-
lactam is currently approved by the French
authorities and would ensure that the comparator
agent was not at a disadvantage during the study.
The relative safety and tolerability of these two
agents were also compared.
Methods
Study design
This was a double-blind, randomized, active con-
trolled, parallel-group trial designed to compare
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gemifloxacin using a 7-day regimen to 10-day
amoxicillin/clavulanate in the treatment of CAP
of suspected pneumococcal origin. The trial format
was conducted according to the guidelines de-
scribed by the Committee on the Consolidation of
Standards for Reporting Trials.12
Study population
Patients eligible for inclusion in the study were 18
years or older with a clinical diagnosis of commu-
nity-acquired bacterial pneumonia characterized
by fever and at least two of the following signs and
symptoms: new or increased cough, purulent
sputum or a change in sputum characteristics, rales
and/or evidence of pulmonary consolidation, or
dyspnoea.
In order to be eligible for study participation, the
patient must have had a chest radiograph showing
the presence of new or progressive infiltrate(s),
consolidation, or pleural effusion consistent with
pneumonia. In addition, the pneumonia was to be
of suspected pneumococcal origin based on at least
two of the following: sudden onset (i.e. o48 h),
chills, pleuritic chest pain, localized alveolar
consolidation on chest radiograph, or Gram-posi-
tive cocci on respiratory sample smear on direct
examination. Patients were excluded for the
following reasons: allergy or severe adverse reac-
tions to carboxyquinolone derivatives or penicillin
or other beta-lactam derivatives; pregnancy or
lactating; history of tendonitis while taking fluor-
oquinolones; phenylketonuria or sensitivity to
aspartame; severe respiratory tract infections
requiring parenteral antimicrobial therapy; pre-
therapy chest radiograph negative for chest infil-
trates, or inconsistent with a CAP diagnosis;
patients with hospital-acquired or aspiration pneu-
monia; patients with localized bronchial obstruc-
tion or a history of post-obstructive pneumonia;
patients with cystic fibrosis, active tuberculosis,
bronchiectasis, or active pulmonary malignancies
or any other complicating infection or disease that
would compromise treatment evaluation of the
study medication; evidence of significant liver or
renal impairment; or needed a concomitant anti-
bacterial agent with a spectrum of activity similar
to the study drugs. Prospective patients were also
excluded if they were HIV positive or otherwise
immunocompromised, if they were taking conco-
mitant sucralfate, probenecid or systemic steroids;
or received previous therapy with a systemic
antibiotic for more than 24 h prior to enrollment.
The study was approved by each investigator’s
institutional review board and all patients gave
written informed consent prior to enrollment.
Study drugs and laboratory assessments
Patients were randomized in blinded fashion at the
first visit in a 1:1 ratio to gemifloxacin 320mg once
daily for 7 days or amoxicillin/clavulanate 1 g/
125mg three times daily for 10 days. Following
random assignment to treatment and to preserve
the study blind, patients received both active and
dummy tablets and sachets as indicated:
Treatment Group A: Oral gemifloxacin 320mg
once daily for 7 days and oral amoxicillin/clavula-
nate-placebo three times daily for 10 days.
Treatment Group B: Oral amoxicillin/clavulanate
1 g/125mg three times daily for 10 days and oral
gemifloxacin-placebo once daily for 7 days.
At the end of therapy, each patient was ques-
tioned regarding the number of tablets and sachets
taken during the study in order to document
patient compliance.
Standardized clinical assessment and bacteriolo-
gic evaluation (Gram stain and sputum culture)
were performed pre-therapy, during therapy (day
2–4), at the end of therapy visit (days 12–14) and at
the follow-up visit (days 24–30). Blood cultures for
bacteriological evaluation were taken at screening,
prior to the first dose of study medication and at
follow-up (day 24–30). Acute and convalescent
phase serological tests for atypical pathogens C.
pneumoniae [MIF; MRL Diagnostics, California, USA]
Legionella pneumophila [IFA, Zeus Scientific Inc.
Raritan, NJ, USA] ‘‘definite’’ a 4-fold increase in
IgG titers to 41:256; ‘‘possible’’ a single IgG titer
of 41:512 or specific IgM anti-Chlamydia 41:16.
Coxiella burnetii [IFA, MRL Diagnostics, California,
USA], ‘‘definite’’, a four-fold increase in phase II
IgG titers or a single phase II IgM titer of 41:80
and, M. pneumoniae [ELISA,CTLLAB,California,
USA] ‘‘possible’’, detection of IgM and were
conducted by the central laboratory, as was an
assay for L. pneumophila sero-group 1 antigen using
urine samples collected from the patients prior to
the first dose of study medication (day 0).
Susceptibility testing was performed according to
NCCLS guidelines.13,14 Haemophilus spp. and M.
catarrhalis also were tested for beta-lactamase
production. S. pneumoniae was tested for penicillin
susceptibility, either by oxacillin disk or by peni-
cillin E-test strip. ECGs were performed prior to
initiation of study drug therapy and once during
therapy on day 2–4.
Two populations were evaluated in this trial
patients for whom drug efficacy could be evaluated
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(per protocol (PP) population; see below) and all
randomized patients who received study drug
(intent-to-treat (ITT) population) for drug safety
evaluation. Two additional populations were also
defined: Bacteriologic PP and Bacteriologic ITT,
which represented patients in the PP and ITT
populations who also had a pre-therapy pathogen
identified (some by isolation and some, atypicals,
by serological methods).
Efficacy/safety measurements
The primary objective of this study was to
demonstrate the non-inferiority of gemifloxacin
relative to amoxicillin/clavulanate with respect to
clinical response and safety at follow-up. Second-
ary objectives were to compare gemifloxacin and
amoxicillin/clavulanate with respect to clinical
response at end of therapy, bacteriologic response
at end of therapy and follow-up, and radiological
response at end of therapy and follow-up. The end
points were radiological, bacteriologic and clinical
response at the end of therapy (days 12–14) and at
follow-up (days 24–30).
Clinical response was based on serial examina-
tions of the patient using objective signs of
auscultatory findings (rales, rhonchi, wheezing,
breath sounds and subjective symptoms). At the
end of therapy, clinical response was graded as
Clinical Success (sufficient improvement or resolu-
tion of the signs and symptoms of CAP recorded at
baseline such that no additional antibacterial
therapy was required for CAP), Clinical Failure
(insufficient improvement or deterioration of signs
and symptoms of CAP such that additional anti-
bacterial therapy was required for CAP), or Unable
to Determine (clinical assessment was not possible
to determine for any reason). The clinical response
at the follow-up visit was reported as: Follow-up
Clinical Success (sufficient improvement or resolu-
tion of signs and symptoms of CAP for patients who
were clinical successes at the end of therapy visit,
such that no additional antibacterial therapy was
required for CAP), Clinical Recurrence (reappear-
ance of signs and symptoms of CAP for patients who
were clinical successes at the end of therapy, such
that additional antibacterial therapy was required
for CAP), or Unable to Determine (patients in whom
a clinical assessment was not possible to deter-
mine).
Bacteriological response was based on the results
of cultures taken before and after therapy. At the
end of therapy, the bacteriological responses were
graded as eradication, presumed eradication (if no
material was available due to a clinical success),
persistence, presumed persistence (no material
was available in a patient considered a clinical
failure), or indeterminate (if bacteriological re-
sponse to the study drug was not evaluable for any
reason). In addition, super-infection was defined as
the presence of pathogen different from the pre-
therapy organism in a symptomatic patient and
requiring additional antimicrobial therapy. Coloni-
zation was defined as the presence of pathogen
different from the pre-therapy organism in an
asymptomatic patient and not requiring additional
antimicrobial therapy. For patients with an end of
therapy response of eradication or presumed
eradication, follow-up bacteriologic eradication
was defined as: follow-up eradication, follow-up
presumed eradication, recurrence (original causa-
tive organism present), presumed recurrence (clin-
ical recurrence but no follow-up sputum or
respiratory sample) and unable to determine (not
evaluable for any reason).
For L. pneumophila, only sputum/respiratory
samples were considered as appropriate forms of
culture. Respiratory samples collected by alterna-
tive methods (e.g. bronchoscopy with protected
specimens [protected brush or telescopic plugged
catheter], transtracheal aspiration, percutaneous
lung or pleural fluid aspiration, or physiotherapy)
were acceptable for other organisms. Patients were
considered positive for this pathogen if L. pneu-
mophila antigen was detected in urine or, if by
serology, there was at least a four-fold rise in L.
pneumophila antibody titre between screening and
follow-up. For M. pneumoniae, C. pneumoniae, and
C. psittaci, there were no possible sources of
culture, i.e., only serology was used for identifica-
tion, and the bacteriological outcome was pre-
sumed on the basis of clinical response. Patients
were considered positive for this pathogen if M.
pneumoniae IgM was detected by serology at
screening and/or follow-up with an immune status
ratio (ISR)X1.1, or M. pneumoniae IgG detected at
follow-up with an ISR X1.1 and with a rise in M.
pneumoniae IgG of X46% between screening and
follow-up. Patients were considered positive for C.
pneumoniae or C. psittaci if either were detected
by serology and met one or more of the following
criteria: there was at least a four-fold rise in C.
pneumoniae or C. psittaci IgG titre between the
screening and follow-up visits and/or there was a C.
pneumoniae or C. psittaci IgM titre of X1:10 at
screening and/or at the follow-up visit.
Radiological outcome was based on the investi-
gator assessment of the posterior–anterior and
lateral chest radiographs obtained at the end of
therapy (day 12–14) and at follow-up (day 24–30)
relative to those obtained at screening. The
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outcome was reported as Improved (improvement
or resolution of radiological signs of CAP), Un-
changed (no improvement in the baseline radiolo-
gical signs of CAP), Worse (worsening of baseline
radiological signs of CAP or appearance of new
radiological signs of CAP) or Unable to Determine (a
valid assessment of radiological outcome could not
be made [e.g. the patient was lost to follow-up]).
The radiological response was then defined on the
basis of the radiological outcome as Success (the
derived radiological outcome was ‘improved’ or
‘presumed improved’), Failure (the derived radi-
ological outcome was ‘unchanged’ or ‘worse’), or
Unable to Determine (the derived radiological
outcome was ‘unable to determine’).
All patients receiving at least one dose of study
drug were evaluable for safety (intent-to-treat
population). Safety was evaluated on the basis of
physical examination findings, ECGs, adverse
events, intercurrent illness and laboratory tests,
including routine hematology, blood chemistry, and
urinalysis tests. Investigators rated each adverse
event subjectively according to relationship to
study drug (probable, possible, remote, or none)
and severity (mild, moderate, severe, or serious or
life threatening).
Statistical analyses
The primary goal of the study was to determine
whether gemifloxacin, given for 7 days was non-
inferior to 10 days of amoxicillin/clavulanate in
patients with CAP. For each evaluation of clinical,
bacteriological and radiological response, a two-
sided 95% confidence interval for the weighted
difference between treatment groups was con-
structed based on the formula of Makuch and
Simon.15 Non-inferiority was defined as the lower
limit of the two-sided 95% confidence interval (CI)
for the difference between groups being greater
than 15%. With the sample size of 240 per-
protocol patients enrolled, the study had a power
of 90% to test the null hypothesis of non-inferiority,
assuming a failure rate of 15% for each treatment
group. An alpha level of 5% was used to assess
significance of main effects and a level of 10% was
used for treatment-covariate interactions. All CIs
for differences in proportions were calculated using
the normal approximation to the binomial distribu-
tion.
Comparisons of the incidence rates of adverse
events between the two study drug groups were
done descriptively. Adverse event reporting was
performed using the World Health Organization
(WHO) coding system. Events were tabulated by
type (according to the COSTART glossary) and by
frequency for all adverse events and for those
events considered to be related to drug treatment.
Results
Of the 324 patients randomized, 320 (99%) patients
comprised the intent-to-treat (ITT) population.
Four patients were excluded from the intent-to-
treat analysis (one in the gemifloxacin group and
three in the amoxicillin/clavulanate group) be-
cause they were withdrawn from the study before
the first dose of study medication had been
administered. Two hundred fifty-four patients
completed the study (134 in the gemifloxacin
group, 120 in the amoxicillin/clavulanate group).
Among those patients who failed to receive a full
course of study drug, adverse events were the main
reason for premature discontinuation of treatment
(gemifloxacin: 9.6%; amoxicillin/clavulanate: 9.8%;
see safety section below). A further 71 patients (39
gemifloxacin; 32 amoxicillin/clavulanate) were
excluded from the Clinical PP populations as a
result of poor visit compliance, treatment with
another systemic antibacterial for inter-current
illnesses, poor study medication compliance, and
a clinical outcome of unable to determine. A total
of 185 patients (95 in the gemifloxacin group and 90
in the amoxicillin/clavulanate group) were ex-
cluded from the Bacteriology ITT population as
they did not have at least one respiratory pathogen
identified at screening. The remaining 72 patients
in the gemifloxacin group and 63 patients in the
amoxicillin/clavulanate group comprised the Bac-
teriology ITT population. One hundred three
patients with a pre-therapy organism identified at
pre-therapy were valid for the efficacy analysis (54
in the gemifloxacin group, 49 in the amoxicillin/
clavulanate group). These patients comprise the
Bacteriology PP population. The most common
reasons for exclusion from the efficacy analysis
were again poor visit compliance, a clinical or
bacteriological outcome of unable to determine, or
prohibited antibacterial therapy for an inter-
current illness.
As shown in Table 1, both treatment groups were
well matched with respect to demographic and
clinical characteristics. Although the data pre-
sented are from the ITT population, similar data
were obtained from the Clinical PP follow-up
population. In the ITT population, the mean age
for patients was 53.3 years in the gemifloxacin
group and 55.3 years in the amoxicillin/clavulanate
group. In both treatment groups there were more
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males (over 62%) than females, and most patients
were white (at least 78% overall). Approximately
one-third of patients in both groups were regular
cigarette smokers. Based on the ATS guideline
stratification,16 not more than 17% of patients in
each treatment group were classified as having a
severe risk of mortality from CAP.
A high proportion of patients were hospitalized
at screening in both the ITT and Clinical PP
populations. Slightly more patients were in-pa-
tients at screening in the amoxicillin/clavulanate
group than the gemifloxacin group (Clinical PP
follow-up population, gemifloxacin: 103/115 pa-
tients, 89.6%; amoxicillin/clavulanate: 111/113
patients, 98.2%). Overall, in the Bacteriology PP
follow-up population, eight gemifloxacin-treated
patients (17.0%) and 11 amoxicillin/clavulanate-
treated patients (23.9%) were bacteremic at
screening. Proportions of bacteremic patients were
similar in the ITT population. Most bacteremic
patients had S. pneumoniae isolated (e.g., in the
Bacteriology PP follow-up population, gemifloxa-
cin: 6/8 patients, 75.0%; amoxicillin/clavulanate:
10/11 patients, 90.9%).
Clinical response
Table 2 illustrates the clinical success rates for
patients treated with either regimen and analyzed
at the various time points assessed during the
study. The primary efficacy parameter was clinical
response at follow-up. As shown in the table, the
clinical success rates at follow-up for the PP
population were 88.7% (102/115) in the gemiflox-
acin group, and 87.6% (99/113) in the amoxicillin/
clavulanate group (95% CI for the treatment
difference:7.3, 9.5). In the ITT population, the
clinical success rates at follow-up were 77.2% (129/
167) in the gemifloxacin group, and 79.1% (121/
153) in the amoxicillin/clavulanate group (95% CI
for the treatment difference:10.9, 7.2). Thus,
gemifloxacin, in both populations, was found to be
at least as clinically effective as amoxicillin/
clavulanate, as the lower limit of the 95% CI for
the treatment difference (gemifloxacin–amoxicil-
lin/clavulanate) was no less than the tolerable limit
set for this study (15%). The success rates at
follow-up in the Bacteriology PP population
(i.e., patients who were clinically valid and
had a pre-therapy pathogen) were 87.2% (41/47)
in the gemifloxacin group and 89.1% (41/46)
in the amoxicillin/clavulanate group (95% CI,
15.0,11.2), indicating that gemifloxacin was also
at least as clinically effective as amoxicillin/
clavulanate in this population. In the Bacteriology
ITT, similar results were noted, with therapeutic
success rates at follow-up similar between treat-
ment groups (gemifloxacin: 75.0%; amoxicillin/
clavulanate: 76.2%).
The clinical success rates at end of therapy were
95.3% (122/128) in the gemifloxacin group and
90.1% (109/121) in the amoxicillin/clavulanate
group for the Clinical PP population. In the ITT
population, clinical success rates at end of therapy
were 85.6% (143/167) and 83.7% (128/153) in the
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Table 1 Demographics and baseline medical characteristics.
Variable Intent-to-treat population
7-day gemifloxacin 320mg qd
(N¼ 167)
10-day amox/clav 1 g/125mg tid
(N¼ 153)
Age, years
Mean (SD) 53.3 (20.4) 55.3 (19.8)
Range 18–97 18–86
Sex, n (%) male 107 (64.1) 96 (62.7)
Race, n (%) caucasian 138 (82.6) 120 (78.4)
History of cigarette smoking
Current smoker, n (%) 45 (28.7) 47 (30.7%)
Smoked regularly in last 59 (35.3) 56 (36.6)
month, n (%)
CAP severityn
Non-severe low risk 70 (41.9) 54 (35.3)
Non-severe moderate risk 71 (42.5) 73 (47.7)
Severe 26 (15.6) 26 (17.0)
nBased on ATS guidelines.16
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gemifloxacin and amoxicillin/clavulanate treat-
ment groups, respectively. Thus, gemifloxacin in
both of these populations was also shown to be at
least as clinically effective as amoxicillin/clavula-
nate. The success rates at this time point in the
Bacteriology PP populations were 96.3% (52/54) in
the gemifloxacin group and 91.8% (45/49) in the
amoxicillin/clavulanate group. In the Bacteriology
ITT, success rates were higher in the gemifloxacin
group than the amoxicillin/clavulanate group (ge-
mifloxacin: 84.7%; amoxicillin/clavulanate: 81%).
Gemifloxacin and amoxicillin/clavulanate were
both clinically effective in patients with S. pneu-
moniae (clinical success rates of 86.4% and 96.4%,
respectively).
There were no clinical failures among the
gemifloxacin-treated patients at end of therapy
with persistence or presumed persistence of S.
pneumoniae alone. Two patients isolated S. pneu-
moniae on entry to the study failed therapy, the
initial pathogens were eradicated but no subse-
quent pathogens were isolated on follow-up.
When severity of CAP (mortality risk) or bacter-
emia at screening were considered, in the Clinical
PP follow-up population, gemifloxacin produced a
higher response rate than amoxicillin/clavulanate.
In this population, patients at severe risk of
mortality from CAP achieved success rates of 100%
in the gemifloxacin group and 88% in the amox-
icillin/clavulanate group. In bacteremic patients,
clinical success rates were 100% in the gemifloxacin
group and 91% in the amoxicillin/clavulanate
group.
Bacteriologic response
Consistent with the design of this study, S.
pneumoniae was the most common pathogen
isolated, being identified in 42% of gemifloxacin-
treated patients and 41% of amoxicillin/clavula-
nate-treated patients. A relatively high number of
M. pneumoniae infections were also identified
serologically (28% in the gemifloxacin group, 32%
in the amoxicillin/clavulanate group). Infection
with L. pneumophila was identified in 11% of
patients and infection with C. pneumoniae 8% of
patients. Most bacteraemic patients had S. pneu-
moniae isolated (gemifloxacin: 6/8 patients, 75.0%;
amoxicillin/clavulanate: 10/11 patients, 90.9%).
Mixed populations of bacteria occurred in 7.8% of
gemifloxacin patients and 10.5% of amoxicillin/
clavulanic acid cases. Patients with two or more
pathogens tended to have infections with both an
atypical organism and typical pathogen (gemiflox-
acin: 8/13 patients; amoxicillin/clavulanate: 12/16
patients). Overall both therapies performed well in
these infections. Only two patients infected with
atypical organisms in mixed populations failed on
gemifloxacin [one case of L. pneumophilaþ S.
aureus and one case of M. pneumoniaeþH.
influenzaeþ S. pneumoniae] while four patients
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Table 2 Clinical success rates at follow-up and end of therapy.
7-day gemifloxacin
320mg qd n=N (%)
10-day amox/clav 1 g/125mg
tid n=N (%)
Follow-up
Clinical PP population 102/115 (88.7) 99/113 (87.6)
95% CI 7.3, 9.5
ITT population 129/167 (77.2) 121/153 (79.1)
95% CI 10.9, 7.2
Bacteriology PP population 41/47 (87.2) 41/46 (89.1)
95% CI 15.0, 11.2
Bacteriology ITT population 54/72 (75.0) 48/63 (76.2)
95% CI 15.7, 13.3
End of therapy
Clinical PP population 122/128 (95.3) 109/121 (90.1)
95% CI 1.2, 11.7
ITT population 143/167 (85.6) 128/153 (83.7)
95% CI 5.9, 9.9
Bacteriology PP population 52/54 (96.3) 45/49 (91.8)
95% CI 4.7, 13.6
Bacteriology ITT population 61/72 (84.7) 51/63 (81.0)
95% CI 9.0, 16.5
714 P. L !eophonte et al.
with atypicals failed on amoxicillin/clavulanate
therapy [L. pneumophila 2; M. pneumoniae 2]. In
all other mixed aetiologies clinical and bacteriolo-
gical success was reported.
In the Bacteriology PP populations, overall
eradication rates were high, with 92.6% (50/54) of
all pathogens in the gemifloxacin group and 96.2%
(51/53) of all pathogens in the amoxicillin/clavu-
lanate group being eradicated or presumed eradi-
cated. Individual eradication rates for the key
pathogens associated with CAP are shown in Table 3.
Eradication rates of M. pneumoniae at end of
therapy were 94% and 83% for the gemifloxacin
group and amoxicillin/clavulanate group, respec-
tively, and the eradication rates of C. pneumoniae
at end of therapy were 100% for both the
gemifloxacin and amoxicillin/clavulanate groups.
Eradication rates of S. pneumoniae at end of
therapy were also high (95.7% and 100% for the
gemifloxacin group and amoxicillin/clavulanate
group, respectively), including against penicillin-
intermediate and resistant strains of S. pneumo-
niae. Of the 19 S. pneumoniae isolates in each
treatment group, 17 isolates (89.5%) in the gemi-
floxacin group and 18 isolates (94.7%) in the
amoxicillin/clavulanate group were either eradi-
cated or presumed eradicated at follow-up.
Six bacteraemic patients (Bacteriology PP follow-
up population) in the gemifloxacin group had S.
pneumoniae isolated from blood at screening.
Gemifloxacin showed a 100% eradication rate in
these bacteraemic patients.
The bacteriological outcomes at follow-up for
the key pathogens associated with CAP were similar
in the Bacteriology ITT population to those of the
Bacteriology PP follow-up population, with a
bacteriological response of eradication or pre-
sumed eradication of 89.2% in the gemifloxacin
group and 92.4% in the amoxicillin/clavulanate
group.
There were no pathogens associated with new
infection at follow-up in either Bacteriology follow-
up populations.
Susceptibility testing
A total of four S. pneumoniae isolates (of the 69
isolated) were resistant to penicillin and nine were
of intermediate susceptibility. All isolates had an
MIC to gemifloxacin of o0.03mg/l with all but one
being either eradicated or presumed eradicated.
One patient experienced clinical and bacteriologi-
cal failure with an isolate of S. pneumoniae
penicillin MIC 4mg/l. All of the isolates with an
elevated penicillin MIC were eradicated by amox-
icillin/clavulanate. Four H. influenzae isolates (of
the 20 isolated) showed intermediate susceptibility
to clarithromycin. One H. influenzae isolate and
one S. pneumoniae isolate were resistant to
clarithromycin, and 16 S. pneumoniae isolates were
resistant to both clarithromycin and azithromycin.
Nine S. pneumoniae isolates were resistant to
cefuroxime, and of these seven isolates were
resistant to both macrolides and cefuroxime. A
total of 5/20 isolates of H. influenzae, 3/3 isolates
of M. catarrhalis and 4/5 isolates of S. aureus were
beta-lactamase positive. In contrast, no isolates
recovered in this study showed evidence of
resistance to ofloxacin at screening.
Radiological response
The radiological success rates at follow-up for the
Clinical PP populations were 90.4% in the gemi-
floxacin group and 87.6% in the amoxicillin/clavu-
lanate group. In the ITT population, success rates
were 79.6% in the gemifloxacin and 79.1% in the
amoxicillin/clavulanate group (see Table 4). Thus,
in both populations gemifloxacin was shown to be
at least as effective as amoxicillin/clavulanate in
terms of radiological response at follow-up. Simi-
larly, the radiological success rates at end of
therapy for both the ITTand PP populations showed
gemifloxacin to be at least as effective as amox-
icillin/clavulanate (see Table 4).
Safety
The safety population comprised 320 patients (167
gemifloxacin and 153 amoxicillin/clavulanate).
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Table 3 Eradication rates for the most common
pre-treatment organisms isolated should indicate
this is mostly presumed eradication.
7-day
gemifloxacin
n=N (%)
10-day
amox/clav
n=N (%)
Follow-up
S. pneumoniae 17/19 (89) 18/19 (95)
H. influenzae 7/9 (78) 5/5 (100)
L. pneumophilia 3/3 (100) 5/5 (100)
M. catarrhalis 3/3 (100) 0/0
S. aureus 2/2 (100) 1/1 (100)
End of therapy
S. pneumoniae 22/23 (96) 21/21 (100)
H. influenzae 11/12 (92) 5/5 (100)
L. pneumophilia 4/5 (80) 5/6 (83)
M. catarrhalis 3/3 (100) 0/0
S. aureus 2/2 (100) 1/1 (100)
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Withdrawals, reported as an adverse event, from
the study occurred in the two cohorts, 33 in each
group, of those withdrawn due to an insufficient
response to therapy two were in the gemifloxacin
group and nine in the amoxicillin/clavulanate
cohort, P ¼ 0:03 (95% CI, 8.8;0.6), a statistically
significant difference Amoxicillin/clavulanate-trea-
ted patients reported more treatment-emergent
events (62.1%) than did the gemifloxacin (58.7%)
group. The most frequently reported adverse
events (X5%) were insomnia, diarrhea and head-
ache for gemifloxacin-treated patients (11.4%, 8.4%
and 5.4%, respectively) and diarrhea and insomnia
for amoxicillin/clavulanate-treated patients (13.1%
and 5.2%). There were no statistically significant
differences between the treatment groups for any
of these events. More patients in the amoxicillin/
clavulanate group were prematurely discontinued
from the study due to adverse events: 8.4% of the
gemifloxacin-treated and 9.8% of those given
amoxicillin/clavulanate.
Drug-related events were reported by 18.6% of
patients in the gemifloxacin group and 22.9% of
patients in the amoxicillin/clavulanate group.
Events occurring in at least 1% of the study
population and considered to be drug-related are
summarized in Table 5. Among these patients, in
the gemifloxacin group, the adverse events most
frequently reported as being of suspected or
probable relationship to study medication were
diarrhea (6.0%) and rash (3.0%). In the amoxicillin/
clavulanate group, the adverse events most fre-
quently reported as being of suspected or probable
relationship to study medication were diarrhea
(11.1%) and fungal infection, vaginitis and vomiting
(all 2.0%). Of note, the incidence of diarrhea of
suspected or probable relationship to study medi-
cation was higher in the amoxicillin/clavulanate
group (11.1%) compared with the gemifloxacin
group (6.0%). Rash was reported in five gemoflox-
acin treated patients and three amoxicillin/clavu-
lanate treated subjects.
Nine gemifloxacin-treated patients (5.4%) and 12
amoxicillin/clavulanate-treated patients (7.8%)
had treatment emergent increases of potential
clinical concern (X3 fold upper limits of normal)
for one or more liver function parameters at the
on-therapy visit, but only two patients (1.3%) in the
amoxicillin/clavulanate group had such elevated
values by the end of therapy. The majority of
elevated liver function parameters were transient,
with lower values being recorded at end of therapy
compared with on-therapy. No patients had abnor-
mal values for total bilirubin at either time point.
ARTICLE IN PRESS
Table 4 Radiologic success rates at follow-up and end of therapy.
7-day gemifloxacin
320mg qd n=N (%)
10-day amox/clav
1 g/125mg tid n=N (%)
Follow-up
Clinical PP population 104/115 (90.4) 99/113 (87.6)
95% CI 5.3, 10.9
ITT population 133/167 (79.6) 121/153 (79.1)
95% CI 8.3, 9.4
End of therapy
Clinical PP population 114/128 (89.1) 106/121 (87.6)
95% CI 6.5, 9.4
ITT population 133/167 (79.6) 122/153 (79.7)
95% CI 8.9, 8.7
Table 5 Drug-related adverse occurring in at least
1% of patients.
7-day
gemifloxacin
n (%)
10-day
amox/clav
n (%)
Adverse event N ¼ 167 N ¼ 153
Diarrhea 10 (6%) 17 (11%)
Rash 5 (3%) 3 (2%)
Vomiting 4 (2%) 3 (2%)
Pneumonia 4 (2%) 3 (o2%)
Erythematous rash 2 (1%) 0
Pruritus 2 (1%) 0
Headache 1 (o1%) 2 (1%)
Hepatocellular damage 1 (o1%) 2 (1%)
Moniliasis 1 (o1%) 2 (1%)
Nausea 1 (o1%) 2 (1%)
Fungal infection 0 3 (2%)
Vaginitis 0 3 (2%)
Therapeutic response
increased
0 2 (1%)
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A total of seven patients died during the study, of
whom 3 were classified as having severe pneumonia
(Fine class IV or V): four in the gemifloxacin group
and three in the amoxicillin/clavulanate group.
None of the adverse events associated with the
deaths was considered by the investigator to be of
suspected or probable relationship to study medi-
cation, and none of the deaths was considered
related to study treatment. In total, 24 gemiflox-
acin-treated patients (14.4%) and 31 amoxicillin/
clavulanate-treated patients (20.3%) reported at
least one serious adverse event. Two serious
adverse events occurred in more than two patients
from each treatment groupFpneumonia (six pa-
tients in the gemifloxacin group) and pulmonary
carcinoma (three patients in each treatment
group). Serious adverse events considered by the
investigator to be related to study medication
occurred for five patients in the gemifloxacin
group: pneumonia and respiratory insufficiency
(one patient), granulocytopenia, pharyngitis (one
patient each) and pneumonia (two patients), and in
four patients in the amoxicillin/clavulanate group:
hallucination, diarrhea (one patient each) and
therapeutic response increased (two patients).
Discussion
This was a randomized, double-blind, double-
dummy, parallel group study designed to evaluate
the efficacy and safety of oral gemifloxacin 320mg
once daily for 7 days versus oral amoxicillin/
clavulanate 1 g/125mg three times daily for 10
days in the treatment of patients with CAP of
suspected pneumococcal origin. The dose of amox-
icillin/clavulanate used is higher than the typical
dose historically prescribed in the USA. The primary
end point of the study was the clinical response at
follow-up (day 23–37), and the secondary efficacy
parameters were clinical response rates at the end
of therapy (day 11–16), the bacteriologic response
rates at end of therapy and at follow-up, and the
radiological response rates at end of therapy and at
follow-up.
The objective of the study was to show that
gemifloxacin was at least as efficacious as high-
dose amoxicillin/clavulanate, that is, that the
lower limit of the 95% CI for the treatment
difference was within a pre-specified non-inferior-
ity margin. The margin stated in this protocol was
15%, and was based on an overall projected
clinical success rate for the study of 85% at follow-
up. Two additional randomized clinical trials of
gemifloxacin in CAP,16,17 for which the entry
criteria did not specifically target pneumococcal
pneumonia, each used a margin of 10% with a
projected success rate of 90% at follow-up. The
wider non-inferiority margin used in this study was
selected because of the increased variability
associated with the lower overall response rate
expected for a group of patients with CAP of
suspected pneumococcal origin.
The two treatment groups were well matched
with respect to demographic and clinical charac-
teristics at baseline. In the ITT population, the
mean age for patients was 53 years in the
gemifloxacin group and 55 years in the amoxicil-
lin/clavulanate group. In both treatment groups
there were more males (over 62%) than females,
and most patients were white (at least 78%
overall). In these patients with suspected pneumo-
coccal pneumonia, 17% of patients in each
treatment group or less were classified as
having severe risk of mortality from CAP, as based
on the ATS guidelines.18 Over 91% of patients in
each group were hospitalized at the time of
randomization.
The results of this study indicated that oral
gemifloxacin 320mg once daily for 7 days is at least
as effective as high-dose oral amoxicillin/clavula-
nate 1 g/125mg three times daily for 10 days for
the treatment of CAP of suspected pneumococcal
origin. The clinical success rates in the Clinical PP
follow-up population were 89% in the gemifloxacin
group and 88% in the amoxicillin/clavulanate group
(95% CI for the treatment difference:7.3, 9.5).
Using the non-inferiority criteria set for the
concurrent gemifloxacin trials (10%), the conclu-
sion of non-inferior efficacy is maintained for the
Clinical PP follow-up population, which is the
primary population of interest. The clinical success
rate at follow-up in the ITT population was 77% for
the gemifloxacin group and 79% for the amoxicillin/
clavulanate group (95% CI for the treatment
difference:10.9, 7.2).
The finding that gemifloxacin was at least as
effective as amoxicillin/clavulanate in the treat-
ment of CAP was supported by the analysis of the
secondary efficacy parameters. In the Clinical PP
follow-up population, clinical success rates at end
of therapy were 95% and 90% in the gemifloxacin
and amoxicillin/clavulanate groups, respectively.
In the Bacteriology PP populations, bacteriological
success rates for the gemifloxacin and amoxicillin/
clavulanate groups were 96% and 92% at end of
therapy and 87% and 89% at follow-up, respectively.
In the Clinical PP populations, radiological success
rates were 89% in the gemifloxacin group and 88% in
the amoxicillin/clavulanate group at end of ther-
apy, and 90% and 88% in the gemifloxacin and
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amoxicillin/clavulanate groups, respectively, at
follow-up.
When severity of CAP (mortality risk) or bacter-
emia on entry were considered, in the Clinical PP
follow-up population, gemifloxacin and amoxicil-
lin/clavulanate both had high response rates. In
patients at severe risk of mortality from CAP the
success rates were 100% in gemifloxacin-treated
patients and 88% in amoxicillin/clavulanate-trea-
ted patients. In bacteraemic patients, clinical
success rates were 100% in the gemifloxacin group
and 91% in the amoxicillin/clavulanate group. It
should be noted, however, that other studies have
shown that addition of a macrolide to a beta-
lactam-based regimen can improve the mortality
rate for bacteremic pneumococcal pneumonia
leading to the suggestion that monotherapy for
these infections may be suboptimal.19,20
A review of recently published literature on trials
with quinolones and high-dose amoxicillin in CAP
indicates that the results observed in this study are
similar to those reported previously. In such
studies, clinical success rates in evaluable patients
ranged from 81% to 91%.21–23 In our study, patients
were treated with gemifloxacin once a day for
seven days. In published studies of a comparator
treatment versus an oral quinolone with fixed
dosage duration, patients received 10 days of
quinolone antibacterial therapy,22,23 and in studies
where the dosage or duration was variable,
patients were elected by the physician to receive
on average 10–13 days of an oral quinolone.22,24
Gemifloxacin was also shown after 7 days treat-
ment to be clinically superior to 7 days of oral
trovafloxacin therapy at some endpoints.17 The
high clinical success rates observed in the current
study with gemifloxacin indicate that good efficacy
can be maintained with a shorter, once-daily, oral
treatment regimens.
The growing incidence of beta lactam and/or
macrolide resistance among S. pneumoniae, H.
influenzae, M. catarrhalis and S. aureus, all of
which were isolated in this study, has limited the
use of some traditional antibacterial agents.7,9
Indeed, recent results of S. pneumoniae suscept-
ibility testing from the TRUST surveillance program
show that from 1998 to 2002, the prevalence of
azithromycin resistance increased by 4.8% to 27.5%,
the prevalence of penicillin resistance increased by
3.7% to 18.4%, the prevalence of ceftriaxone
resistance increased by 0.5% to 1.7%, and the
prevalence of levofloxacin resistance increased by
0.3% to 0.9%.25 In this context, a number of key
initial pathogens showed evidence of resistance to
beta-lactams or to macrolides in this study: 5.8%
(4/69) S. pneumoniae isolates were resistant to
penicillin and 13% (9/69) were of intermediate
susceptibility; 1.4% (1/69) were resistant to clari-
thromycin alone, and 23% (16/69) were resistant to
both clarithromycin and azithromycin; 13% (9/69)
were resistant to cefuroxime, of which 77.8% (7/9)
were resistant to both macrolides and cefuroxime.
Additional data from both Doern et al. and Jacobs
et al. from US-isolated strains of S. pneumoniae
showed an increasing incidence of multi-drug
resistant isolates with around 25% having resistance
to three or more antimicrobials in 2000.26,27
However, caution must be shown due to the recent
cases of levofloxacin therapy failure among isolates
of S. pneumoniae in which clinical failure has been
accompanied by emergence of levofloxacin resis-
tance. To date over 25 such cases have been
reported and in most tested strains gemifloxacin
has retained activity at concentrations achievable
in respiratory tissues.28,29 Given this worrying
trend, it has been suggested that the newer RTI
fluoroquinolones (e.g., gemifloxacin, moxifloxacin)
should only be considered empiric treatment
options for adults with CAP of suspected drug-
resistant pneumococcal origin.30 Current data and
opinion suggest that if a quinolone antimicrobial is
to be prescribed then the initial selection of the
most potent agent should provide optimal clinical
and microbiological outcomes as well as minimize
the selection of resistance.28
Both antibacterial treatments were highly effec-
tive in the eradication of the key pathogens of CAP,
with overall eradication rates of 94% for gemiflox-
acin and 93% for amoxicillin/clavulanate treatment
groups at end of therapy, in the Bacteriology PP end
of therapy population. This suggests that gemiflox-
acin can provide appropriate coverage when used
as an empirical therapy in CAP, as cover for both
the typical pathogens and atypical organisms was
provided. Eradication rates of S. pneumoniae at
end of therapy were high (95.7% and 100% for the
gemifloxacin group and amoxicillin/clavulanate
group, respectively), and gemifloxacin was also
seen to be highly effective in penicillin-intermedi-
ate and resistant strains of S. pneumoniae. Six
bacteraemic patients (Bacteriology PP follow-up
population) in the gemifloxacin group had S.
pneumoniae isolated from blood at screening.
Gemifloxacin showed a 100% eradication rate in
these bacteraemic patients. This is particularly
encouraging in light of data from Kelley et al.
describing breakthrough pneumococcal bacteremia
in patients treated with azithromycin and clari-
thromycin.31
Consistent with the published literature and the
design of this study, S. pneumoniae was the most
common pathogen isolated (40% of patients overall,
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where a causative pathogen was identified). Of
interest was the relatively high number of M.
pneumoniae infections detected by serology (28% in
the gemifloxacin group, 32% in the amoxicillin/
clavulanate group), and patients with L. pneumo-
phila and C. pneumoniae (11% and 8% overall,
respectively). This would indicate that, while the
inclusion criteria used for this study increased the
likelihood of pneumococcal pneumonia, they do not
exclude patients with atypical pathogens. This
could have been a concern, given the comparator’s
historically weak activity against atypical patho-
gens, yet both drugs fared well against these
organisms. This may reflect that the patients
suffered for a mild form of pneumonia or that
legionellosis (such as with M. and C. pneumoniae)
may be self-limiting. We should further acknowl-
edge that our study design was limited by the fact
that our definition of a ‘‘typical’’ pneumococcal
syndrome has not been definitively demonstrated in
the literature. Treatment failures could not be
explained in terms of underlying CAP mortality risk
and the interaction between treatment and this
covariate was not statistically significant. More-
over, it was not possible to draw conclusions on an
association between MIC and treatment failure,
because the range of gemifloxacin MICs at screen-
ing was generally low. In some patients, treatment
failures could be explained on the basis of the
patient’s underlying co-morbidities (e.g., emphy-
sema, COPD).
From a safety perspective, gemifloxacin was well
tolerated. The most frequently reported adverse
events (X5% incidence) in the gemifloxacin group
were insomnia, diarrhea and headache (11.4%, 8.4%
and 5.4%, respectively). In the amoxicillin/clavu-
lanate group, the most frequently reported adverse
events were diarrhea and insomnia (13.1% and
5.2%, respectively). There were no statistically
significant differences between the treatment
groups for any adverse events with an incidence
of X5%. The numbers of patients with transiently
elevated liver function tests or other laboratory
values of potential clinical concern were low and
similar in both treatment groups. There was an
incidence of 3% rash and 1% erythematous rash in
the gemifloxacin arm. The rash is mild to moderate
in severity and has been more commonly observed
in patients under the age of 40 years and who
took drug for more than 7 days and the rash
resolves within 7 days. The rash shows no evidence
of phototoxicity, vasculitis, or necrosis. Seven
deaths were reported during the study (four in
the gemifloxacin group and three in the
amoxicillin/clavulanate group); none of the ad-
verse events associated with the deaths were
considered to be related to study medication.
Serious adverse events were reported for 24
patients (14.4%) in the gemifloxacin group and 31
patients (20.3%) in the amoxicillin/clavulanate
group. However, these adverse events were con-
sidered by the investigator to be drug-related for
only five patients (3.0%) in the gemifloxacin group
and four (2.6%) in the amoxicillin/clavulanate
group. The proportion of discontinuations due to
adverse events was lower in the gemifloxacin
group (gemifloxacin: 8.4%, amoxicillin/clavula-
nate: 9.8%).
In summary, this study has shown that oral
gemifloxacin 320mg once daily for 7 days is at
least as effective clinically, bacteriologically, and
radiologically as oral, high-dose amoxicillin/clavu-
lanate 1 g/125mg three times daily for 10 days in
the treatment of patients with CAP of suspected
pneumococcal origin. Given the comparable ad-
verse experience profiles for gemifloxacin and
amoxicillin/clavulanate, these data suggest that
gemifloxacin is an effective alternative to amox-
icillin/clavulanate and offers a more convenient
dosing regimen.
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